GenInCode POSITIVE THROMBO INCODE CLINICAL RESULTS

Link to Full Article GENinCode Plc are pleased to announce the publication of its Thrombo inCode® prospective case-control study performed at the Karolinska Institute, Sweden. The positive clinical results strengthen Thrombo inCode® as a leading diagnostic for the diagnosis of inherited thrombophilia and venous thromboembolism (“VTE”). The study returned positive clinical results which strengthen Thrombo […]

GenInCode ADMISSION TO TRADING RNS

Link to Full Article GENinCode the predictive genetics and cardiovascular disease company focused on the prevention of cardiovascular disease is thrilled to announce the completion of its IPO and subsequent listing on the London Stock Exchange. NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF IRELAND OR […]

GENINCODE ANNOUNCES MAJOR US COMMERCIALISATION PARTNERSHIP WITH EVERSANA

Link to Full Article GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces its partnership with EVERSANA Life Sciences LLC (“EVERSANA”) as its launch and commercialisation partner to access the United States market for the GENinCode portfolio of polygenic cardiovascular disease (“CVD”) products focused on genetic risk. EVERSANA is a […]

GEN INCODE ANNOUNCES MAJOR UK COLLABORATION WITH ROYAL BROMPTON AND HAREFIELD HOSPITALS

Link to Full Article GEN inCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces today a collaboration with Royal Brompton and Harefield hospitals (“RB&H”), recently merged with Guy’s and St Thomas’ NHS Foundation Trust (“GSTT”), to provide globally leading cardiovascular disease clinical genetic testing and reporting. GEN inCode specializes […]

GEN INCODE APPOINTS NEW CHAIRMAN

Link to Full Article GENinCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the appointment of Bill Rhodes as non-executive Chairman of the Company, effective 1 January, 2021. Bill Rhodes is a Chairman with a proven, demonstrable international track record in the Life Sciences and […]

GEN INCODE APPOINTS NEW CHAIRMAN

Link to Full Article GENinCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the appointment of Bill Rhodes as non-executive Chairman of the Company, effective 1 January, 2021. Bill Rhodes is a Chairman with a proven, demonstrable international track record in the Life Sciences and […]

GEN INCODE APPOINTS CHIEF FINANCIAL OFFICER

Link to Full Article GEN inCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease announces today the appointment of Paul Foulger as Chief Financial Officer to the Company. Paul Foulger is an experienced CFO with a proven, demonstrable track record in the Biotech industry for both AIM […]